Intuitive Quantitation

To determine key scientific features of successful drugs, we focused the IQuant engine on the top 10 drugs based on 2023 sales. Here is a small sample of what we found. IQuant integrates information from many sources, uncovering new paths for current product development projects. Contact us to learn how we can enhance your program. https://lnkd.in/gXtCJFxq

Read more about our important research to better identify impactful concepts and people in disease research.

Go beyond citation metrics when identifying collaborators, advisors or key opinion leaders in your research program. IQuant technology has been designed to avoid all the "cats" out there. https://lnkd.in/gWeV2sMA

Clearly, citations no longer can be considered the primary measure of scientific impact or influence. https://lnkd.in/dSmhuj7g We have built the IQuant engine to address this growing problem. Take a look at our unique and innovative answers (https://lnkd.in/gXtCJFxq). #DrugDevelopment #Biotechnology #DrugDiscovery #MedicalAffairs #AdvisoryBoards

Free the data! Solving the Publisher Problem with IQuant Why do we rely solely on publicly available data at Iquant? As Iquant’s senior data scientist, I’ve spent a lot of time reflecting on the source of the information that’s available to us. The choice to use only publicly available data isn’t one that we took lightly. The high cost of premium data services might be the most obvious reason, but on a deeper level we are fundamentally opposed to the excessive, profit-driven model employed by both scientific publishing and other data services companies.  These complaints are by no means revolutionary. For upwards of 20 years there has been a growing movement towards open access to publications along with louder criticism of the pay-per-view science and institutionally priced subscription services models. Open access could be a solution, but unfortunately, open access publishers continue to collect their toll. They simply have shifted the costs from consumers to those submitting their work through increasingly exorbitant processing fees. In the quest for greater scientific understanding, this becomes an unethical roadblock. These publishing business models have unfortunately created a scientific information landscape that resembles the rest of our society. One where the ‘haves’ maintain their status without impediment, while the ‘have-nots’ continue to struggle for the recognition and impact they clearly deserve. This inequality within the scientific community poses all the same problems that it does within society as a whole. New, exciting, thinking could be lost - whether merely by circumstance and location, or more nefariously by publishers enforcing their own bias. Can we trust the impartiality of a system when the driving motivation seems not to be advancement of knowledge, but rather, ever-increasing profits?  At Iquant we are not able to justify supporting such a system – not as some grand gesture (our size precludes anything using the word grand) - simply as scientists, who fundamentally believe in the principles of transparency and diversity of thought.  Publishers would have you believe that that all the answers are waiting to be accessed behind their paywalls, but data means very little without careful analysis. I believe that there exists a vast trove of knowledge and insight to be found in public, open access, sources. While the information is freely accessible, we have the skills necessary to synthesize it into valuable results. By extracting and carefully analyzing all the information available we are in a position to create novel insights and draw compelling conclusions from freely available data. This is why we built the Iquant Engine, to help other scientists reach their goals without contributing to a system that we profoundly disagree with. -Benjamin Verdoorn, Chief Data Scientist

Read more about our important research to better identify impactful concepts and people in disease research.

While there’s been lots of talk about how best to measure scientific impact, IQuant has been doing something about it. Citations have been the workhorse metric for this, but relying solely on them has well-known flaws. IQuant has developed a new approach that complements and enhances citation metrics for identifying the most impactful research and investigators. These unique and proprietary tools are fully integrated in the IQuant Engine and are now part of every report we generate. If you are looking for better Key Opinion Leaders, or want to accelerate your biopharma development contact us for a fresh approach.  #medicalaffairs, #medicalscienceliaison, #drugdevelopment, #drugdiscovery, #biotechnology https://lnkd.in/gDsJWtKp